Related Experiment Video
Updated: May 7, 2026
23:53
Ole Isacson: Development of New Therapies for Parkinson's Disease
Published on: April 29, 2007
Therapeutic prospects for Parkinson disease
C Warren Olanow1, Anthony H V Schapira
1Departments of Neurology and Neuroscience, Mount Sinai School of Medicine, New York, NY.
Annals of Neurology
|September 17, 2013
Summary
Current Parkinson's disease (PD) treatments like levodopa have limitations. New therapies are needed to address side effects, non-motor symptoms, and disease progression for better patient outcomes.
Area of Science:
- Neuroscience
- Pharmacology
- Neurology
Background:
- Levodopa and surgical interventions have significantly advanced Parkinson's disease (PD) treatment.
- Despite current therapies, many PD patients experience persistent disability and limitations.
- Existing treatments often fail to adequately manage non-motor symptoms and disease progression.
Purpose of the Study:
- To review the limitations of current dopaminergic and surgical therapies for Parkinson's disease.
- To identify critical unmet therapeutic needs in Parkinson's disease management.
- To explore emerging strategies and challenges in developing novel Parkinson's disease treatments.
Main Methods:
- Literature review of current and experimental Parkinson's disease therapies.
- Analysis of the efficacy and side effect profiles of existing treatments.
- Examination of research addressing non-motor symptoms and disease modification.
Main Results:
- Dopaminergic therapies, while beneficial, are associated with significant side effects.
- Non-motor and non-dopaminergic symptoms (e.g., freezing, dementia) remain poorly controlled.
- Current treatments do not halt the progressive nature of Parkinson's disease.
Conclusions:
- There is a critical need for safer dopaminergic therapies for Parkinson's disease.
- Novel treatments must target non-motor symptoms and disease modification.
- Overcoming obstacles in research and development is essential for advancing Parkinson's disease therapy.
Related Concept Videos
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:11Direct-Acting Cholinergic Agonists: Therapeutic Uses
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren syndrome.
01:11Alterations in Muscle Tone lll
Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...